Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities
Source : https://www.sciencedirect.com/science/article/pii/S0304419X2300077X?via=ihub
Author links open overlay panel Lizhuo Zhang a b 1 , Qingqing Feng c 1 , Jiafeng Wang a b , Zhuo Tan a b , Qinglin Li d ,...
Relevance: Here, we discuss and summarize the molecular basis of TC, review molecularly targeted therapeutic drugs in clinical research, and explore potentially novel molecular therapeutic targets. We focused on the evaluation of current and recently emerging tyrosine kinase inhibitors approved for systemic therapy for TC, including...
TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37261522/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Patients with co-occurring TP53/CDKN2A/B variations and ALK/RET/ROS1 rearrangements are associated with high TMB, more neoantigens, an immunosuppressive microenvironment and a worse prognosis.
To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37261523/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Many gene mutations have been shown to be associated with immunotherapy efficacy. Gene mutations should be combined with PD-L1, TMB, etc. to predict the effect of immunotherapy.
Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37265026/
Rearranged during transfection (RET) fusions and epidermal growth factor receptor (EGFR) mutations are potent oncogenic drivers in patients with nonsmall cell lung cancer (NSCLC), but rarely co-exist. Concurrent RET/EGFR mutations...
Conclusions/Relevance: These data may support the use of selpercatinib in patients with RET/EGFR co-mutated NSCLC.
Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37236546/
Rare NTRK-driven malignant neoplasms can be effectively inhibited by anti-TRK agents. The discovery of NTRK1/2/3-rich tumors in papillary thyroid cancer (PTC) patients is a precondition for the rapid identification of...
Conclusion: NTRK rearrangements comprising 10 fusion types were highly concentrated in BRAF and RET double-negative PTCs in the authors’ series. Two novel fusions (EZR::NTRK1 and EML4::NTRK2) and the main fusion-pattern NTRK1/3 were determined. Based on this retrospective cohort study (summarized in Figure 1), an optimal algorithm for NTRK...